| RRC ID |
76738
|
| Author |
Togami K, Zhan X, Ishizawa K, Miyakoshi K, Miyao A, Quan P, Chono S.
|
| Title |
Development of LOX-1 Antibody Modified Immuno-liposomes as Drug Carriers to Macrophages in Atherosclerotic Lesions.
|
| Journal |
Pharmazie
|
| Abstract |
We developed a drug delivery system for atherosclerotic lesions using immuno-liposomes. We focused on enhancing the delivery efficiency of the liposomes to macrophages in atherosclerotic lesions by antibody modification of lectinlike oxidized low-density lipoproteins (LDL) receptor 1 (LOX-1). The cellular accumulation of the liposomes in foam cells induced by oxidized LDL (oxLDL) in Raw264 mouse macrophages was evaluated. The cellular accumulation of LOX-1 antibody modified liposomes in oxLDL-induced foam cells and untreated Raw264 cells was significantly higher compared with that of unmodified liposomes. The liposomes were also administered intravenously to Apoeshl mice as an atherosclerosis model. Frozen sections were prepared from the mouse aortas and observed by confocal laser microscopy. The distribution of LOX-1 antibody modified liposomes in the atherosclerotic regions of Apoeshl mice was significantly greater compared with that of unmodified liposomes. The results suggest that LOX-1 antibody modified liposomes can target foam cells in atherosclerotic lesions, providing a potential route for delivering various drugs with pharmacological effects or detecting atherosclerotic foci for the diagnosis of atherosclerosis.
|
| Volume |
78(8)
|
| Pages |
113-116
|
| Published |
2023-8-1
|
| DOI |
10.1691/ph.2023.3004
|
| PMID |
37592420
|
| MeSH |
Animals
Antibodies
Apolipoproteins E
Atherosclerosis* / drug therapy
Drug Carriers
Liposomes*
Macrophages
Mice
Scavenger Receptors, Class E
|
| IF |
1.198
|
| Resource |
| Human and Animal Cells |
RAW 264(RCB0535) |
